20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ESOMEPRAZOLE MAGNESIUM USP, with a corresponding US DMF Number 29639.
Remarkably, this DMF maintains an Active status since its submission on September 01, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 27, 2024, and payment made on February 23, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II